How much does a box of Capivasertib cost?

Capivasertib is a new type of targeted drug mainly used to treat adult patients with hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with PIK3CA, AKT1 or PTEN gene alterations. This drug is often combined with fulvestrant to increase the effectiveness of the treatment. Clinical trial results show that capositinib can significantly delay disease progression and improve patient survival rates in these specific patient groups.

The mechanism of capositinib mainly works by inhibiting theAKT signaling pathway. AKT is an important intracellular signaling molecule and plays a key role in the occurrence and development of various tumors. By intervening in this pathway, capositinib can effectively prevent the proliferation and growth of tumor cells. For patients whose disease has progressed despite at least one endocrine therapy, capositinib offers a new treatment option, especially for those with specific biomarker alterations.

Currently, capositinib has been on the market for a short time in China, so patients face certain challenges in obtaining the drug. However, in the international market, the original product of this drug is sold in Europe for about more than 60,000 yuan, which may be a considerable burden for many patients. In order to meet market demand, some countries (such as Laos) have also begun to produce corresponding generic drugs, with a more affordable price of about more than 3,000 yuan. These generic drugs are not only more advantageous in terms of cost, but also have almost the same ingredients as the original drugs and can basically achieve the same curative effect, providing patients with more choices.

During the use of capositinib, patients need to regularly monitor relevant biomarkers to evaluate the therapeutic effect and adjust the medication regimen. At the same time, doctors need to pay attention to the patient's overall health and deal with possible side effects and adverse reactions in a timely manner.

Reference materials:https://www.drugs.com/mtm/capivasertib.html